| Features: |
| Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes. Radiosensitizer Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer. |
| Source: |
| Type: protein |
| Trx is a small protein that acts as a reducing agent, donating electrons to reduce oxidized proteins and other molecules. Trx is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer. - Cytosolic thioredoxin (TRX-1) and mitochondrial thioredoxin (TRX-2). - Thioredoxin is a pivotal redox regulator that protects cells from oxidative stress and supports survival and proliferation. - There is interest in combining thioredoxin inhibitors with conventional chemotherapy or radiotherapy to sensitize tumors to oxidative stress and improve treatment efficacy. |
| 1987- | PTL, | Rad, | A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PrEC |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:201 Target#:824 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid